Oxford, UK, 26 April 2022 – Argonaut Therapeutics, a leading developer of novel cancer agents, gave a company showcase presentation at the BioTrinity 2022 event, an international conference focused on bio-partnering and investment. The presentation to an audience of key…
Oxford, UK, 21 January 2021 – Argonaut Therapeutics, a leading developer of novel cancer agents, announced the appointment of Dr Chan Hee Park to its Board of Directors, representing key investor, JW Pharmaceutical Corporation. Dr Park is the Chief Technological…
Oxford, UK, 1 August 2020 – Argonaut Therapeutics, a leading developer of novel cancer agents, announced the appointment of Mr Nick Dixon-Clegg to its Board of Directors, representing key investor, Oxford Sciences Innovation. Nick is a Principal at OSI and…
The investment will advance Argonaut’s Therapeutics’ arginine methylation inhibitor drug candidate towards the clinic and enable continued expansion of its drug discovery pipeline. Oxford, UK, March 2019 – Argonaut Therapeutics, a leading developer of novel cancer therapies, announced that it…